The disutility of chronic gout

被引:33
作者
Khanna, Dinesh [1 ,2 ]
Ahmed, Mansoor [3 ]
Yontz, Dustin [4 ]
Ginsburg, Shaari S. [3 ]
Park, Grace S. [1 ]
Leonard, Anthony [5 ]
Tsevat, Joel [3 ,4 ,5 ,6 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90095 USA
[3] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA
[4] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[5] Univ Cincinnati, Inst Study Hlth, Cincinnati, OH USA
[6] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA
关键词
gout; preference-based measures; health status; health utility; health-related quality of life;
D O I
10.1007/s11136-008-9355-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction Gout is a chronic painful inflammatory arthritis. Data regarding the impact of gout on health-related quality of life, however, are limited. Methods We interviewed patients with chronic stable gout. Health status was measured by using the Short Form 36 (SF-36) physical component summary (PCS) and physical component summary (MCS) and the Health Assessment Questionnaire-Disability Index (HAQ-DI). Direct preference-based measures included a health rating scale (RS), the time tradeoff (TTO), and standard gamble (SG) for one's current health state with gout and current health state without gout; indirect preference-based measures included the SF-6D and the EQ-5D. Disutilities for gout were assessed by subtracting preference scores for current health states with gout from those for current health without gout and were compared between patients ranking gout as their top health concern versus the rest of the patients. Results Of the 80 interviewees, 72 (90%) were male, 55 (69%) were Caucasian, and the mean (SD) age was 60 (11) years. The mean SF-36 PCS and MCS scores were 38.9 and 48.6, respectively. The mean (SD) SF-6D score was 0.68 (0.13) and the mean (SD) EQ-5D score was 0.73 (0.23). The mean (SD) RS disutility for gout was 0.05 (0.12), the mean TTO disutility was 0.03 (0.12), and the mean SG disutility was 0.02 (0.11). The RS disutilities of subject patients who ranked gout as their top concern (n = 17) trended towards being statistically significantly larger than those of the remaining patients, P = 0.06 but their TTO and SG disutilities were similar to those of the remaining patients. Conclusions Although physical functioning of patients with gout is often compromised, patients with chronic stable gout do not assign a large disutility to gout per se. Still, patients who rank their gout as their top health concern tend to assign greater RS disutility to gout than do other patients.
引用
收藏
页码:815 / 822
页数:8
相关论文
共 30 条
[1]  
Arias Elizabeth, 2004, Natl Vital Stat Rep, V53, P1
[2]   Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population [J].
Bharmal, Murtuza ;
Thomas, Joseph, III .
VALUE IN HEALTH, 2006, 9 (04) :262-271
[3]   The estimation of a preference-based measure of health from the SF-36 [J].
Brazier, J ;
Roberts, J ;
Deverill, M .
JOURNAL OF HEALTH ECONOMICS, 2002, 21 (02) :271-292
[4]   Deriving a preference-based single index from the UK SF-36 Health Survey [J].
Brazier, J ;
Usherwood, T ;
Harper, R ;
Thomas, K .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1115-1128
[5]  
Colton T, 1974, STAT MED
[6]  
*EUROQOL GROUP, 1990, HLTH POLICY
[7]   MEASUREMENT OF PATIENT OUTCOME IN ARTHRITIS [J].
FRIES, JF ;
SPITZ, P ;
KRAINES, RG ;
HOLMAN, HR .
ARTHRITIS AND RHEUMATISM, 1980, 23 (02) :137-145
[8]   METHODOLOGY FOR MEASURING HEALTH-STATE PREFERENCES .2. SCALING METHODS [J].
FROBERG, DG ;
KANE, RL .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1989, 42 (05) :459-471
[9]   Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores [J].
Hanmer, Janel ;
Lawrence, William F. ;
Anderson, John P. ;
Kaplan, Robert M. ;
Fryback, Dennis G. .
MEDICAL DECISION MAKING, 2006, 26 (04) :391-400
[10]  
Hays R.D., 2005, Assessing quality of life in clinical trials: Methods and practice, P25